샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779817

혼합 백신 시장

Combination Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 373 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 혼합 백신 시장은 2030년까지 96억 달러에 도달

2024년에 55억 달러로 추정되는 세계의 혼합 백신 시장은 분석 기간인 2024-2030년에 CAGR 9.8%로 성장하며, 2030년에는 96억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 소아 연령층은 CAGR 11.9%를 기록하며, 분석 기간 종료시에는 54억 달러에 달할 것으로 예측됩니다. 성인 연령층 부문의 성장률은 분석 기간 중 CAGR 7.4%로 추정됩니다.

미국 시장은 15억 달러로 추정, 중국은 CAGR 13.7%로 성장 예측

미국의 혼합 백신 시장은 2024년에 15억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 13.7%로 추이하며, 2030년까지 20억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 6.8%와 8.7%로 예측됩니다. 유럽에서는 독일이 CAGR 약 7.7%로 성장할 것으로 예측됩니다.

세계의 혼합 백신 시장 - 주요 동향과 촉진요인 정리

혼합백신이란 무엇이며, 예방접종 프로그램에 어떤 혁명을 가져올 것인가?

혼합백신은 한 번의 주사로 여러 가지 감염병을 예방할 수 있는 첨단 예방접종 제제입니다. 이 백신은 서로 다른 병원체의 항원을 한 번에 접종할 수 있도록 설계되어 강력한 면역 반응을 유지하면서 예방접종에 필요한 주사 횟수를 줄일 수 있습니다. 일반적인 혼합백신에는 DTP(디프테리아, 파상풍, 백일해), MMR(홍역, 볼거리, 풍진), B형 간염과 B형 독감균(Hib)을 포함한 5가지 질병을 예방하는 5가 백신 등이 있습니다.

혼합백신 도입이 확대됨에 따라 백신 접종 준수율을 높이고, 물류 문제를 완화하며, 전반적인 백신 접종률을 향상시킴으로써 전 세계 예방접종 프로그램에 변화를 가져오고 있습니다. 혼합백신은 주사 횟수를 최소화함으로써, 특히 의료 접근성이 제한된 지역에서 소아 및 성인의 예방접종 스케줄을 간소화할 수 있습니다. 각국 정부와 보건기관이 질병 예방과 확산 방지를 최우선 과제로 삼고 있는 가운데, 혼합백신은 적은 수의 의료 서비스로 여러 질병을 효과적으로 예방할 수 있는 세계 백신 전략의 중요한 툴로 부상하고 있습니다.

백신 기술의 발전은 혼합 백신을 어떻게 강화시키고 있는가?

차세대 혼합백신 개발은 생명공학, 재조합 DNA 기술, 보조제제의 발전에 의해 추진되어 왔습니다. 최신 혼합백신은 안전성이나 유효성을 떨어뜨리지 않고 면역반응을 높이기 위해 재조합 단백질 서브유닛, 바이러스 벡터 플랫폼, 합성 펩티드를 활용하고 있습니다. 또한 항원 안정화의 발전으로 내열성 백신의 제조가 가능해져 엄격한 콜드체인 보관의 필요성이 감소하고 원격지에서의 예방 접종에 대한 접근성이 확대되고 있습니다.

개선된 보조제 시스템 또한 혼합 백신의 면역원성을 향상시키고, 반응성을 최소화하면서 장기적인 예방 효과를 보장합니다. mRNA 기반 혼합 백신과 같은 혁신적인 기술은 신흥 전염병에 대해 보다 유연하고 신속하게 적응할 수 있는 솔루션을 제공하기 위해 연구되고 있습니다. 또한 비침습적 전달 시스템 및 마이크로니들 패치는 환자의 순응도 및 투여 편의성을 향상시키기 위해 혼합 백신 제제에 통합되고 있습니다. 연구가 진행됨에 따라 전염병 대책, 맞춤형 예방접종 프로그램 및 광범위한 공중보건 구상에서 중요한 역할을 할 것으로 예측됩니다.

혼합백신 수요를 주도하는 질병과 인구는?

소아기 예방접종 프로그램은 생명을 위협하는 감염으로부터 조기에 보호하기 위해 다항원 제제에 크게 의존하고 있으므로 소아 인구는 혼합 백신의 가장 큰 소비자층이 되고 있습니다. 세계 각국의 예방접종 일정에서는 DTP-Hib-HepB 5가 백신 등 혼합백신이 우선적으로 사용되고 있으며, 최소한의 주사로 종합적인 질병 예방을 실현하고 있습니다. 또한 HPV(인유두종바이러스), 독감, 폐렴구균 감염증 등의 질병에 대한 혼합백신을 접종하는 청소년 및 성인층이 증가하고 있습니다.

신종 및 재유행 감염병의 위협이 증가함에 따라 혼합백신에 대한 수요가 급증하고 있습니다. 또한 혼합백신은 특정 지역에서 흔한 여러 병원체에 대한 예방 효과가 있으므로 여행 및 군 예방접종 프로그램도 시장 확대에 기여하고 있습니다. 또한 항생제 내성 세균 감염이 증가함에 따라 예방접종의 중요성이 높아지고 있으며, 혼합백신 연구개발에 대한 투자가 더욱 촉진되고 있습니다. 세계보건기구가 질병 퇴치와 예방접종의 형평성을 지속적으로 강조하는 가운데, 혼합백신은 다양한 인구 집단에서 높은 예방접종률을 달성하는 데 필수적인 역할을 할 것으로 기대되고 있습니다.

혼합백신 시장의 성장 원동력은?

혼합백신 시장의 성장은 백신 개발의 발전, 세계 예방접종 구상 증가, 소아 및 성인 예방접종 프로그램에 대한 수요 증가, 비용 효율적인 질병 예방 전략의 필요성 등 여러 가지 요인에 의해 주도되고 있습니다. 세계보건기구(WHO)와 질병통제예방센터(CDC)와 같은 정부 기관은 백신으로 예방 가능한 질병을 줄이고 공중보건 성과를 향상시키기 위해 정기적인 예방접종 일정의 일부로 혼합백신을 장려하고 있습니다.

백신 혁신을 위한 연구 협력과 자금 지원 확대는 새로운 다항원 제제 개발을 가속화하고 시장 성장을 더욱 강화하고 있습니다. 또한 감염병의 유행과 팬데믹 대응이 활발해지면서 신속한 예방접종 대응에 있으며, 혼합백신의 중요성이 부각되고 있습니다. 백신 제조에 대한 투자 증가, 공급망 인프라 강화, 새로운 혼합백신에 대한 규제 당국의 승인은 시장 확대를 더욱 촉진하고 있습니다. 기술의 발전이 계속되고 전 세계에서 예방접종 보급에 대한 관심이 높아지면서 혼합백신 시장은 지속적인 성장세를 보이며 예방의료와 감염병 대응의 미래를 변화시킬 것으로 예측됩니다.

부문

연령층(소아, 성인), 기술(컨쥬게이트, 라이브, 재조합, 불활성화, 톡소이드, 기타 기술), 최종사용자(병원, 진료소, 기타 최종사용자)

조사 대상 기업의 예

  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CanSino Biologics Inc.
  • CSL Limited(Seqirus)
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc(GSK)
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corporation
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Valneva SE

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.11

Global Combination Vaccines Market to Reach US$9.6 Billion by 2030

The global market for Combination Vaccines estimated at US$5.5 Billion in the year 2024, is expected to reach US$9.6 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Pediatric Age Group, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Adult Age Group segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 13.7% CAGR

The Combination Vaccines market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Combination Vaccines Market - Key Trends & Drivers Summarized

What Are Combination Vaccines and How Are They Revolutionizing Immunization Programs?

Combination vaccines are advanced immunization formulations that protect against multiple infectious diseases through a single injection. These vaccines are designed to deliver antigens from different pathogens in a single dose, reducing the number of injections required for immunization while maintaining strong immune responses. Common combination vaccines include DTP (diphtheria, tetanus, and pertussis), MMR (measles, mumps, and rubella), and pentavalent vaccines that protect against five diseases, including hepatitis B and Haemophilus influenzae type B (Hib).

The increasing adoption of combination vaccines is transforming global immunization programs by improving compliance, reducing logistical challenges, and enhancing overall vaccine coverage. By minimizing the number of injections, combination vaccines help streamline pediatric and adult vaccination schedules, particularly in regions where access to healthcare is limited. As governments and health organizations prioritize disease prevention and outbreak control, combination vaccines are emerging as a key tool in global vaccination strategies, ensuring effective protection against multiple diseases with fewer healthcare visits.

How Are Advancements in Vaccine Technology Enhancing Combination Vaccines?

The development of next-generation combination vaccines has been fueled by advancements in biotechnology, recombinant DNA technology, and adjuvant formulation. Modern combination vaccines utilize recombinant protein subunits, viral vector platforms, and synthetic peptides to enhance immune response without compromising safety or efficacy. Additionally, advancements in antigen stabilization have enabled the creation of thermostable vaccines, reducing the need for stringent cold chain storage and expanding access to immunization in remote areas.

Improved adjuvant systems are also enhancing the immunogenicity of combination vaccines, ensuring long-lasting protection while minimizing reactogenicity. Innovations such as mRNA-based combination vaccines are being explored to provide more flexible and rapidly adaptable solutions against emerging infectious diseases. Furthermore, needle-free delivery systems and microneedle patches are being integrated into combination vaccine formulations to improve patient compliance and ease of administration. As research progresses, combination vaccines are expected to play a crucial role in pandemic preparedness, personalized immunization programs, and broader public health initiatives.

Which Diseases and Populations Are Driving the Demand for Combination Vaccines?

The pediatric population represents the largest consumer base for combination vaccines, as childhood immunization programs rely heavily on multi-antigen formulations to provide early protection against life-threatening infections. National immunization schedules worldwide prioritize combination vaccines such as the DTP-Hib-HepB pentavalent vaccine to ensure comprehensive disease prevention with minimal injections. Additionally, adolescent and adult populations are increasingly receiving combination vaccines for diseases such as HPV (human papillomavirus), influenza, and pneumococcal infections.

The demand for combination vaccines has surged in response to the growing threat of emerging and re-emerging infectious diseases. Travel and military vaccination programs have also contributed to market expansion, as combination vaccines provide protection against multiple pathogens common in specific geographic regions. Additionally, the increasing incidence of antibiotic-resistant bacterial infections has reinforced the importance of preventive immunization, further driving investment in combination vaccine research and development. As global health organizations continue to emphasize disease eradication and immunization equity, combination vaccines are expected to play an integral role in achieving high vaccination coverage across diverse populations.

What Is Driving the Growth of the Combination Vaccines Market?

The growth in the combination vaccines market is driven by several factors, including advancements in vaccine development, rising global immunization initiatives, increasing demand for pediatric and adult immunization programs, and the need for cost-effective disease prevention strategies. Government agencies, such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), are promoting combination vaccines as part of routine immunization schedules to reduce vaccine-preventable diseases and improve public health outcomes.

The expansion of research collaborations and funding for vaccine innovation has accelerated the development of new multi-antigen formulations, further strengthening market growth. Additionally, the rise of infectious disease outbreaks and pandemic preparedness efforts have highlighted the importance of combination vaccines in rapid immunization responses. Increasing investments in vaccine manufacturing, enhanced supply chain infrastructure, and regulatory approvals for novel combination vaccines are further driving market expansion. With continued technological advancements and the increasing emphasis on global immunization coverage, the combination vaccines market is expected to witness sustained growth, transforming the future of preventive healthcare and infectious disease control.

SCOPE OF STUDY:

The report analyzes the Combination Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Age Group (Pediatric Age Group, Adult Age Group); Technology (Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology, Other Technologies); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CanSino Biologics Inc.
  • CSL Limited (Seqirus)
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc (GSK)
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corporation
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Combination Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Childhood Immunization Programs Spur Demand for Combination Vaccines
    • Rising Healthcare Costs and Resource Constraints Strengthen the Case for Multi-Disease Vaccine Formulations
    • Improved Compliance and Reduced Clinic Visits Drive Adoption of Combination Immunization Schedules
    • Advancements in Adjuvant and Delivery Systems Enhance Efficacy of Multi-Valent Vaccines
    • Expansion of National Immunization Programs in Emerging Economies Boosts Market Penetration
    • Stringent Cold Chain and Logistics Challenges Highlight the Efficiency of Single-Dose Combination Vaccines
    • Growing Threat of Disease Resurgence Due to Vaccine Hesitancy Propels Government Push for Coverage Expansion
    • Development of Combination Vaccines for Adult Immunization Opens New Market Segments
    • Integration of COVID-19 With Influenza and RSV Vaccines Expands Preventive Health Opportunities
    • Regulatory Support and Accelerated Approvals for Multi-Target Vaccines Facilitate Market Growth
    • Increased Awareness of Pediatric Disease Prevention Sustains Long-Term Demand
    • Partnerships Between Pharma Giants and Global Health Organizations Drive Distribution in Underserved Regions
    • R&D Focus on Novel Antigen Compatibility Strengthens Innovation Pipelines for Combination Vaccines
    • Rising Incidence of Co-Infections and Multi-Disease Burden Fuels Need for Broad-Spectrum Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Combination Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Combination Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Conjugate Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Conjugate Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Conjugate Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Live Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Live Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Live Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Recombinant Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Recombinant Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Recombinant Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Inactivated Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Inactivated Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Inactivated Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Toxoid Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Toxoid Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Toxoid Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • JAPAN
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • CHINA
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • EUROPE
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Combination Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • FRANCE
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • GERMANY
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Combination Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • INDIA
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Combination Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Combination Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030
  • AFRICA
    • Combination Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Combination Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Combination Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Combination Vaccines by End-Use - Clinics End-Use, Other End-Users and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Combination Vaccines by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Other End-Users and Hospitals End-Use for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Combination Vaccines by Technology - Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Combination Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate Technology, Live Technology, Recombinant Technology, Inactivated Technology, Toxoid Technology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제